FibroGen announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FGEN:
- FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
- FibroGen, AstraZeneca terminate U.S./RoW roxadustat collaboration agreement
- FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
- FibroGen reports Q4 EPS (57c), consensus (42c)
- FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
